Epigenetic profiling of Italian patients identified methylation sites associated with hereditary transthyretin amyloidosis
- PMID: 33203445
- PMCID: PMC7672937
- DOI: 10.1186/s13148-020-00967-6
Epigenetic profiling of Italian patients identified methylation sites associated with hereditary transthyretin amyloidosis
Abstract
Hereditary transthyretin (TTR) amyloidosis (hATTR) is a rare life-threatening disorder caused by amyloidogenic coding mutations located in TTR gene. To understand the high phenotypic variability observed among carriers of TTR disease-causing mutations, we conducted an epigenome-wide association study (EWAS) assessing more than 700,000 methylation sites and testing epigenetic difference of TTR coding mutation carriers vs. non-carriers. We observed a significant methylation change at cg09097335 site located in Beta-secretase 2 (BACE2) gene (standardized regression coefficient = -0.60, p = 6.26 × 10-8). This gene is involved in a protein interaction network enriched for biological processes and molecular pathways related to amyloid-beta metabolism (Gene Ontology: 0050435, q = 0.007), amyloid fiber formation (Reactome HSA-977225, q = 0.008), and Alzheimer's disease (KEGG hsa05010, q = 2.2 × 10-4). Additionally, TTR and BACE2 share APP (amyloid-beta precursor protein) as a validated protein interactor. Within TTR gene region, we observed that Val30Met disrupts a methylation site, cg13139646, causing a drastic hypomethylation in carriers of this amyloidogenic mutation (standardized regression coefficient = -2.18, p = 3.34 × 10-11). Cg13139646 showed co-methylation with cg19203115 (Pearson's r2 = 0.32), which showed significant epigenetic differences between symptomatic and asymptomatic carriers of amyloidogenic mutations (standardized regression coefficient = -0.56, p = 8.6 × 10-4). In conclusion, we provide novel insights related to the molecular mechanisms involved in the complex heterogeneity of hATTR, highlighting the role of epigenetic regulation in this rare disorder.
Keywords: Amyloidosis; Epigenetics; Methylation; Modifier gene; Val30Met mutation; hATTR.
Conflict of interest statement
Drs. Fuciarelli and Polimanti received research grants from Pfizer Inc. to conduct epigenetic studies of hATTR. The other authors reported no biomedical financial interests or potential conflicts of interest.
Figures



Similar articles
-
In silico analysis of TTR gene (coding and non-coding regions, and interactive network) and its implications in transthyretin-related amyloidosis.Amyloid. 2014 Sep;21(3):154-62. doi: 10.3109/13506129.2014.900487. Epub 2014 Apr 29. Amyloid. 2014. PMID: 24779883
-
THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.Curr Med Res Opin. 2013 Jan;29(1):63-76. doi: 10.1185/03007995.2012.754348. Epub 2012 Dec 13. Curr Med Res Opin. 2013. PMID: 23193944 Clinical Trial.
-
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS).Amyloid. 2022 Dec;29(4):228-236. doi: 10.1080/13506129.2022.2070470. Epub 2022 Jun 22. Amyloid. 2022. PMID: 35730447
-
Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.Amyloid. 2018 Sep;25(3):143-147. doi: 10.1080/13506129.2018.1531842. Amyloid. 2018. PMID: 30486687 Review.
-
Hereditary transthyretin cardiac amyloidosis proven by endomyocardial biopsy: a single-centre retrospective study and literature review.Acta Cardiol. 2024 Jun;79(4):436-443. doi: 10.1080/00015385.2023.2257521. Epub 2023 Sep 28. Acta Cardiol. 2024. PMID: 37768132 Review.
Cited by
-
The genetics of cardiac amyloidosis.Heart Fail Rev. 2022 Sep;27(5):1485-1492. doi: 10.1007/s10741-021-10164-z. Epub 2021 Sep 13. Heart Fail Rev. 2022. PMID: 34518987 Review.
-
Altered gut microbiota in Taiwanese A97S predominant transthyretin amyloidosis with polyneuropathy.Sci Rep. 2024 Mar 14;14(1):6195. doi: 10.1038/s41598-024-56984-5. Sci Rep. 2024. PMID: 38486098 Free PMC article.
-
Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability.J Neurol. 2024 Sep;271(9):5746-5761. doi: 10.1007/s00415-024-12509-8. Epub 2024 Jun 22. J Neurol. 2024. PMID: 38907862 Free PMC article. Review.
-
Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future.Neurotherapeutics. 2021 Oct;18(4):2286-2302. doi: 10.1007/s13311-021-01154-y. Epub 2021 Nov 30. Neurotherapeutics. 2021. PMID: 34850359 Free PMC article. Review.
-
Epigenomic Profiles of African-American Transthyretin Val122Ile Carriers Reveals Putatively Dysregulated Amyloid Mechanisms.Circ Genom Precis Med. 2021 Feb;14(1):e003011. doi: 10.1161/CIRCGEN.120.003011. Epub 2021 Jan 11. Circ Genom Precis Med. 2021. PMID: 33428857 Free PMC article.
References
-
- Parman Y, Adams D, Obici L, Galan L, Guergueltcheva V, Suhr OB, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29(Suppl 1):S3–S13. doi: 10.1097/WCO.0000000000000288. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous